For the first time, the FDA has approved a drug for people with nonalcoholic fatty liver disease. Though Rezdiffra isn't for all patients, it may be helpful for the millions of Americans who have NASH (nonalcholoic steatohepatitis) or MASH (metabolic dysfunction-associated steatohepatitis). University Hospitals hepatology specialist, Pierre Gholam, MD, explains the ramifications of this breakthrough medicine.

University Hospitals is one of the nation’s leading health care systems, providing patient-centered care that meets the highest standards for quality and patient safety and have received numerous awards and recognitions from some of the most prestigious institutions in the country for our leadership and exceptional patient outcomes. As an accountable care organization, we foster long-term patient-provider relationships that help promote preventive care, increase wellness and healthy behaviors, decrease emergency episodes, and prevent hospitalizations. To learn more: [ Ссылка ]

свернуть